{"id":"W3095325704","doi":"10.1182/blood-2020-137393","title":"Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bosutinib; Imatinib; Medicine; Myeloid leukemia; Nilotinib; Internal medicine; Imatinib mesylate; Oncology; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003672626,0.0006422772,0.000929789,0.00006038123,0.0003404275,0.0000970757,0.0006134109,0.0003503953,0.0007150835],"category_scores_gemma":[0.002334948,0.0004868998,0.0005891876,0.0004009621,0.0002147624,0.0001660871,0.0001906821,0.000702539,0.0004374175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002379197,"about_ca_system_score_gemma":0.005223208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005666763,"about_ca_topic_score_gemma":0.0003301012,"domain_scores_codex":[0.9958712,0.0001367107,0.001082656,0.001158149,0.0007389189,0.001012381],"domain_scores_gemma":[0.9957159,0.001922135,0.0004756569,0.001228841,0.0001317736,0.0005257064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7048153,0.005698074,0.0004694039,0.0007695311,0.006560324,0.001415218,0.006111442,0.0002944867,0.01965465,0.0005826915,0.164918,0.08871084],"study_design_scores_gemma":[0.8779953,0.01564333,0.0004793144,0.0002894245,0.002413064,0.0000211448,0.0002711383,0.002370276,0.01216756,0.00005287154,0.0877748,0.0005217948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807519,0.002681843,0.0001261341,0.005219392,0.001086295,0.005371727,0.002739704,0.0003536478,0.001669351],"genre_scores_gemma":[0.9784806,0.0005073115,0.002152726,0.0009095989,0.0123216,0.0007729371,0.004166855,0.0001871807,0.0005011444],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1731799,"threshold_uncertainty_score":0.9997582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06081154179105686,"score_gpt":0.3156738313909531,"score_spread":0.2548622895998962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}